Christopher Vann, Chief Operating Officer 

Oct. 12 | 4:45pm | UBC Ballroom 

London, UK 


In-person Presentation 

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled, and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms, and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions